Status:
COMPLETED
6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)
Lead Sponsor:
Organon and Co
Conditions:
Schizophrenia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This is an extension study of A7501013 (P05771/NCT00145496) to further test the efficacy and safety of Asenapine compared with a marketed agent (olanzapine) in the treatment of patients with persis...
Eligibility Criteria
Inclusion
- Continue to meet all demographic and procedural
- inclusion criteria of the A7501013 trial to enter into
- this extension trial.
- Have demonstrated an acceptable degree of compliance
- and completed the A7501013 trial, and would benefit
- from continued treatment according to the investigator.
Exclusion
- Have an uncontrolled, unstable clinically significant
- medical condition.
- Have been judged to be medically noncompliant in the
- management of their disease.
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
196 Patients enrolled
Trial Details
Trial ID
NCT00174265
Start Date
July 1 2005
End Date
May 1 2009
Last Update
February 9 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.